Repligen Stock Price, News & Analysis

Repligen Corporation (NASDAQ:RGEN) has renewed its exclusive supply agreement with Purolite to develop affinity ligands for monoclonal antibodies, extending the partnership to 2032. This agreement allows Purolite to access new mAb fragment ligands developed at Avitide and strengthens Repligen's role in the supply of Protein A ligands. The collaboration aligns with Repligen's strategy to enhance market adoption of its Praesto® affinity resin portfolio and secure supply of agarose-based Protein A resins, further establishing their leadership in bioprocessing technologies.

Repligen Corporation (NASDAQ:RGEN) will report its Q3 2022 financial results on November 1, 2022. A press release will be issued before market opening, followed by a conference call at 8:30 a.m. EDT to discuss updates and results for the three and nine month periods ending September 30, 2022.

The call is accessible at (844) 274-3999 (domestic) or (412) 317-5607 (international). A webcast will also be available on the investor relations section of Repligen's website.

Repligen Corporation (NASDAQ:RGEN) has announced a strategic collaboration and exclusive license agreement with DRS Daylight Solutions, lasting 15 years. This partnership aims to enhance the use of mid-infrared (mid-IR) technology in bioprocessing. Repligen will commercialize Daylight's Culpeo® and develop additional products focused on Quantum Cascade Laser mid-IR solutions. This will facilitate real-time monitoring of critical biological manufacturing processes, improving production yields and ensuring product quality.

Repligen Corporation (NASDAQ:RGEN) has announced its upcoming Investor Day 2022 on September 20 in New York City, scheduled from 8:20 to 11:30 a.m. EDT. This live event will feature presentations from the leadership team, followed by a Q&A session. Attendees can register for the in-person event, which is limited to institutional investors and analysts, or access the live webcast on the company's Investor Relations website. A replay will be available post-event.

Repligen Corporation (RGEN) reported record revenue of $207.6 million for Q2 2022, marking a 27% increase year-over-year, with 29% organic growth. The company raised its revenue guidance for the full year 2022 to a range of $790 million to $810 million, up from the previous $770 million to $800 million. Q2 GAAP gross margin was 58.5%, and diluted EPS rose to $0.88, compared to $0.64 in Q2 2021. The strong performance was driven by significant growth in the base business, particularly in Filtration and Chromatography segments.

Repligen Corporation (NASDAQ:RGEN) will report its second quarter 2022 financial results on August 2, 2022, before the market opens. A conference call will follow at 8:30 a.m. EDT to discuss business updates and financial results for the period ending June 30, 2022. Investors can access the call via toll-free numbers for domestic and international callers and will also be available as a webcast on the company's website. The event will be archived for later access.

Repligen Corporation (NASDAQ:RGEN) has appointed Konstantin Konstantinov, Ph.D., to its Board of Directors. With nearly 30 years in the life sciences and bioprocessing industries, Dr. Konstantinov currently serves as Chief Technology Officer at Codiak BioSciences. His experience includes leadership roles at Genzyme and Bayer Healthcare, focusing on the development of biologic drugs and continuous biomanufacturing. The Board expresses optimism about his technical leadership and expertise in bioprocessing, which aligns with Repligen's mission to innovate in the bioprocessing sector.

Repligen Corporation (NASDAQ:RGEN) announced its participation in three upcoming investor conferences. These include the Craig-Hallum 19^th Annual Institutional Investor Conference on June 1, the William Blair 42^nd Annual Growth Stock Conference in Chicago from June 6-9, where CEO Tony J. Hunt will present on June 7, and the Jefferies Global Healthcare Conference in New York from June 8-10, with CFO Jon K. Snodgres presenting on June 9. Live webcasts of these presentations will be available on Repligen's Investor Relations website.

Repligen Corporation (NASDAQ:RGEN) reported first-quarter 2022 revenue of $206.4 million, reflecting a 45% year-over-year growth. Organic revenue surged by 44%, with base business growth at 37%.

COVID-related sales constituted 26% of total revenue. The company anticipates a decline in COVID-related demand but expects strong growth from its base products. Adjusted EPS rose to $0.92 from $0.68 year-over-year. For the full year, RGEN revises its revenue guidance down to $770-$800 million, adjusting expectations for COVID-related revenue.